The Pharma Data

MARCH 8, 2021

This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo. The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Drug Discovery World

JANUARY 24, 2024

Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. This has hindered development of drugs so that, from a therapeutic intervention point of view, fibrosis research is still in its infancy.

Research 59

Research Gene Expression Drugs Development 59

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. Vigil Neuroscience. Led by industry veteran Ivana Magov?evi?-Liebisch

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Pharmaceutical Technology

FEBRUARY 13, 2023

The continued high level of interest in small molecules presents multiple opportunities to select a candidate that is ‘developable’, with subsequent rapid progression toward first-in-human (FIH) clinical testing. Therefore, it is vital to choose molecules for pharmaceutical development very carefully.

Development 130

Development In-Vivo Clinical Trials Clinical Trials 130